Trials / Conditions / Glioblastoma Multiforme (GBM)

Glioblastoma Multiforme (GBM)

21 registered clinical trials studyying Glioblastoma Multiforme (GBM) — 12 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EG NCT07326566	Black Diamond Therapeutics, Inc.	Phase 2
Recruiting	5G-PEARL: Paxalisib in Malignant Brain Tumours NCT07391215	Institute of Cancer Research, United Kingdom	Phase 1 / Phase 2
Recruiting	Early Phase Study of KESONOTIDE™in Participants With Solid Tumours NCT06926075	Filamon LTD	Phase 1 / Phase 2
Not Yet Recruiting	The Effect of Glioblastoma PSMA Expression Following Tumour VEGF Blockade From Bevacizumab NCT07052877	Royal North Shore Hospital	—
Recruiting	Focused Ultrasound Blood-Brain Barrier Disruption for the Treatment of High-Grade Glioma in Patients Undergoin NCT07179328	Sunnybrook Health Sciences Centre	Phase 1
Not Yet Recruiting	Photodynamic Therapy for Glioblastoma Multiforme Based on Metaverse and Yellow Fluorescence NCT06939400	Zhejiang Provincial People's Hospital	—
Recruiting	Allogeneic γδT Cells in Glioblastoma NCT07144735	Peking University Third Hospital	N/A
Not Yet Recruiting	Patient's Derived Organoids for Drug Screening in Glioblastoma NCT06781372	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	N/A
Active Not Recruiting	A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer NCT06521567	GlaxoSmithKline	Phase 1 / Phase 2
Recruiting	5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours NCT06630260	Institute of Cancer Research, United Kingdom	Phase 1 / Phase 2
Recruiting	5G-EMERALD: Amivantamab in Malignant Brain Tumours NCT06632236	Institute of Cancer Research, United Kingdom	Phase 1
Recruiting	JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM) NCT06595186	JenKem Technology Co., Ltd.	Phase 2
Active Not Recruiting	ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme NCT04587830	Polaris Group	Phase 2
Completed	Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma NCT04019002	Susan Chang	Phase 1
Completed	PriCoTTF Study: TTFields Before and During Radiotherapy for Newly Diagnosed Glioblastoma NCT07120620	Sied Kebir	Phase 1 / Phase 2
Withdrawn	Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevaci NCT01788280	University of Utah	Phase 2
Recruiting	Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM NCT03213002	Northwell Health	Phase 1 / Phase 2
Terminated	Study of Induction of Hypothyroxinemia Adjunct to Conventional Therapies in GBM Patients NCT02654041	Musli Thyropeutics Ltd.	Phase 2
Completed	TAU-2014-1: Mibefradil and Hypofractionated Re-Irradiation Therapy in Recurrent GBM NCT02202993	Cavion, Inc.	Phase 1
Completed	CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM NCT01109095	Baylor College of Medicine	Phase 1
Completed	Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GB NCT01238237	Northwell Health	Phase 1